Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial

Overall test agreement was 92.7% (95% CI 90.7-94.4%). From a patient-level view, 58.7% were negative on both assays, 32.9% positive on both, and 8.6% discordant (ctDNA detected by RaDaR but not dPCR in 9 patients, and the reverse in 3). Among ctDNA-positive patients, 55.2% were first detected by RaDaR, 5.2% by dPCR, and 39.6% at the same timepoint (P<0.001). Median lead time to relapse was 7.1 months with RaDaR vs 5.7 months with dPCR.

San Antonio Breast Cancer Symposium 2022PubMed 36423745